Lund, Sweden, 2012-10-30 08:30 CET (GLOBE NEWSWIRE) -- EXINI Diagnostics AB (NASDAQ OMX First North: EXINI) and Active Biotech AB (NASDAQ OMX NORDIC: ACTI) start collaboration within clinical trials. The aim is to use the opportunity offered by EXINI Bone™ to monitor disease progression in advanced prostate cancer, using the BSI (Bone Scan Index) value, a new imaging biomarker. BSI is thought to be useful in studying the effect of tasquinimod in the treatment of patients with castrate-resistant prostate cancer (CRPC)
